Phase 4 N=20 Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine
Influenza
Primary: Number of Participants Who Shed Virus — 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=123 A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis
Skin Diseases
Primary: Time to the First Relapse of AD During the Maintenance Phase — NA; 142.0 Days — p=<0.0001
N/A N=12 Role of Skeletal Muscle Nitric Oxide Production in Age-related Fatigue and Fatigability
Fatigue · Aging
Primary: Change in Muscle Fatigue After 1 Week of Placebo or Sildenafil — 107; 115; 54; 158 percent change of successful repetitions — p=0.02
Phase 3 N=404 Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk
Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12 — 0.27; 3.91; -73.70; -69.98 percent change — p=<0.001
Phase 2 N=26 Bone Tissue Engineering Using Autologous Bone Repair Cell (BRC) Therapy for Sinus Floor Bone Augmentation
Tooth Loss
Primary: Bone Mineral Density of Bone Core — .79; .78 mg/mm^3
Phase 2 N=25 Viagra in the Treatment of Primary Dysmenorrhea
Dysmenorrhea
Primary: The Primary Outcome Was Total Pain Relief Over 4 Hours (TOPAR4), Comparing a Single Dose of Sildenafil 100 mg to a Single Dose of Placebo. — 11.9; 6.4 units on a scale…
Phase 3 N=164 Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen
Primary Hypercholesterolemia · Mixed Dyslipidemia
Primary: Percentage of Participants With Full Administration of Evolocumab at Both Weeks 4 and 8 — 93.9; 91.5 Percentage of participants
N/A N=67 Pain Control for Intrauterine Device Placement: A Trial of Ketorolac Prior to Intrauterine Device Placement
Pain Control With IUD Insertion
Primary: VAS (Visual Analogue Scale) Measurement of Pain — 5.2; 3.6 units on a scale — p=0.99
Phase 2 N=160 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects
Hyperlipidemia
Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 — -14.76; -40.77; -42.58; -50.70 percent change — p=<0.001
Phase 3 N=16 Physiologic Comparison Between NIV-NAVA and PS in Preterm Infants
Noninvasive Neurally Adjusted Ventilatory Assist and Pressure Support in Preterm Infants
Primary: Trigger Delay — 35.2; 294.6 ms — p=<0.001
N/A N=795 Treatment-Resistant Depression Registry
Major Depressive Disorder
Primary: Montgomery Asberg Depression Rating Scale (MADRS)% Responders (>/= 50% Improvement From Baseline) — 24; 8.8; 28; 13.8 Percentage of Participants — p=<.0001
Phase 2 N=50 Efficacy of Methotrexate in Myasthenia Gravis
Myasthenia Gravis
Primary: Total Prednisone Dose Area Under the Curve — 2996.6; 3484.7 mg*Months — p=0.26
N/A N=299 Illness Management and Recovery Treatment Integrity Scale Validation and Leadership Intervention Development
Severe Mental Illness
Primary: Illness Management and Recovery Scale — 3.72 units on a scale — p=<0.01
Phase 4 N=12 Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) — 12; 7; 5; 0 participants
Phase 2 N=9 Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye
Dry Eye · Sjogren's Syndrome · Graft vs. Host Disease
Primary: Safety — 0; 0 event